Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Napabucasin Fails in PIII for Colorectal Cancer: Sumitomo Dainippon
February 10, 2021
- Japan Ethical Drug Sales Down 3.9% in December: Crecon
February 9, 2021
- Rakuten Medical’s Photoimmunotherapy Now Available in Japan
February 9, 2021
- 7 Japan Drug Majors See 2.7% Revenue Fall in FY2020, COVID-19 Forces Cuts on Guidance: Jiho Tally
February 8, 2021
- 1st Oral GLP Agent Hits Japan Shelves
February 8, 2021
- Chugai COO Okuda to Become CEO, Kosaka to Stay as Chairman
February 8, 2021
- Chugai Targets 1 Global Product Launch Each Year: New Growth Strategy
February 8, 2021
- Kyowa Kirin Aims for CAGR of 10% towards 500 Billion Yen Target by 2025: New Biz Plan
February 8, 2021
- Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
- MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
February 5, 2021
- Gilead Mulling Japan Entry into PIII Study for Inhaled Version of Veklury
February 5, 2021
- Kyowa Kirin’s 2020 Sales Rise 4.1% on Growth of 3 Strategic Products
February 5, 2021
- Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
February 5, 2021
- Takeda’s 9-Month Sales Skid 3.6% on Dips in Rare Diseases, Neuroscience
February 5, 2021
- PI/IIa Study for AnGes’ Hypertension Vaccine Confirms Antibody Production
February 5, 2021
- Otsuka Teams Up with US Firm on Development of Gene Testing Kit for Blood Cancers
February 5, 2021
- Daiichi Sankyo Kicks Off Global PII of ADC Patritumab for EGFR-Mutated NSCLC
February 5, 2021
- Kaken to Copromote Mochida’s Forteo Follow-On from April
February 5, 2021
- Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
February 4, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…